George Vlachogiannis, Managing Editor at Cancer Control, shared a post on LinkedIn:

“A comprehensive clinicogenomic analysis of data from ~4,000 patients with lung adenocarcinoma (LUAD) obtained from the MSK MetTropism cohort identifies key clinical and genetic markers associated with bone metastases—a major driver of morbidity and poor outcomes in advanced NSCLC.

Key findings:

Bone metastases were linked to specific co-metastases (e.g., liver, CNS) and mutations in TP53, EGFR, KEAP1, and MYC.
Poor prognosis in bone metastatic LUAD was associated with age >75, female sex, EGFR wild-type status, and mutations in KEAP1, MYC, KRAS, and SMARCA4.

Observations can improve risk stratification and inform targeted monitoring strategies.”

Lung Adenocarcinoma With Bone Metastases: Clinicogenomic Profiling and Insights Into Prognostic Factors

Authors: Ahmed H. Al Sharie et al.

George Vlachogiannis: A major driver of morbidity and poor outcomes in advanced NSCLC